31 October 2019
Artificial Pancreas Device System (APDS) Market Forecast 2020-2030: Forecasts and Analysis By Type (Control – to – Range (CTR) System, Threshold Suspended Device System, and Control – to – Target (CTT) System), by Treatment Type (Bi-hormonal, Insulin Only, and Hybrid) and Geography, with Profiles of Leading Companies, with Profiles of Leading Companies report provides impartial Artificial Pancreas Device System (APDS) sector analysis.
According to the report published by Visiongain, the Artificial Pancreas Device System (APDS) market is estimated to be valued at USD 187.3 million in 2020 and is expected grow at a CAGR of 20.2% during the forecast period 2020-2030. The artificial pancreas (AP) is an internally carried medical device that mimics the biological pancreas ' endocrine role by controlling blood glucose (BGL) levels. It infuses insulin and potentially glucagon to regulate BGL to type 1 diabetic disease in a more streamlined fashion according to an suitable monitoring law. Offering movement, efficiency since using digital communication methods and sophisticated software algorithms it will automatically regulate and control the amount of glucose. In addition to preventing hyperglycemia (increase in glucose concentrations), which in the course of moment contributes to the growth of complications such as: heart, kidney, nose, muscle and foot harm, cardiovascular diseases and Alzheimer's, while hypoglycemia (fall in glucose concentrations) can be distressing and lead to coma or mortality.
An artificial pancreas, according to the FDA, is a medical device that connects a glucose monitor to an insulin infusion pump where the pump automatically decreases and raises subcutaneous insulin delivery using a command algorithm according to defined subcutaneous glucose concentrations. Because control algorithms can vary significantly, there are a variety of artificial pancreas device systems currently under development. These systems span a wide range of designs from low glucose suspend (LGS) device systems to the more complex bihormonal control-to-target systems.
Artificial Pancreas Device System (APDS) Market is witnessing Growth due to factors such as
Over the years, diabetes technology has developed continuously to enhance performance of lives and patient care. In Type 1 diabetes (T1DM) leadership, frequent blood glucose (BG) controls and numerous regular insulin injections have become normal treatment. Continuous glucose monitoring (CGM) enables nurses in their glycemic control to monitor and discern patterns. These systems enhance the value of lives with preset alerts for hypoglycemia for relatives and caregivers. Since their advent on the industry, insulin engines have proceeded to enhance and innovate. Hybrid closed-loop devices used the information collected using CGM to help with the dosage of basal insulin and the avoidance of hypoglycemia. As technology remains to advance, nurses are inclined to have to forcibly input less and less data into their pump system. In the future, we are probable to see a scheme that needs no direct feedback from patients and enables consumers to consume all day without adding carbohydrates or reaching blood sugars. As technology remains to move forward, endocrinologists and diabetes suppliers need to remain up-to-date to best direct their clients in using evolving leadership instruments to optimize their use.
Future Directions In the last 20 years of clinical treatment, continuous glucose controls have greatly enhanced. In order to enable greater surveillance and governance during physical exercise and times of fast glucose modifications, future CGMs will need to enhance the lag period of present machines. As these products proceed to evolve, detectors and antennas are probable to decrease and decrease skin texture to facilitate wearability. Additionally, to maintain these equipment in position, fresh adhesive techniques need to be used as a sensor's lifespan remains to enhance. CGMs are already being used in closed-loop hybrid systems with insulin pumps ; at the same time, more collaborations are ongoing to make CGM devices currently available compatible with other independent insulin pumps with the aim of developing a closed loop and suspending them in the near future before low systems.
FDA has described 3 main categories of artificial pancreas device systems:
- Threshold Suspend Device System With novice suspension cell devices, also known as small glucose suspension devices, insulin delivery is stopped for a fixed moment when 2 concentrations of glucose are below a defined low level of hypoglycemia
- Control-to-Range System With these technologies, the person establishes his or her own insulin dose within a defined scope, but if glucose concentrations achieve outside that scope (greater or smaller), the artificial pancreas apparatus scheme carries over. Patients using this form of scheme still require blood glucose concentrations to be checked and insulin given as required.
- Control-to-target scheme The device seeks to keep glucose concentrations close to a goal point, such as 100 mg / dL, with this sort of scheme. Control-to-target devices are automatic and involve no customer involvement except for the ongoing glucose surveillance device calibration. Several apparatus subtypes such as those delivering insulin-only, bi-hormonal devices, and hybrid systems are being created.
The market is divided into limit blocked unit scheme, CTR scheme, and CTT scheme based on the sort of instrument. The frozen phone threshold system retained the biggest market share in 2015. This system requires action automatically when the person is unable to react to the suspended warning limit and prevents insulin delivery when the price of sensor glucose approaches a small limit.
During the forecast period, the CTT System is expected to experience the highest development with 37.6 percent CAGR. It is a fully automated system that minimizes customer response. It is anticipated that such variables will fuel market growth.
Shift in Trends
The emerging markets in the developing economies are anticipated to be the key variable that offers the main competitors greater and more profitable development possibilities to grow their company and regional scope. The developing nations ' evolving economies are the main variable that gives significant competitors a stronger chance to grow their company. These become a significant justification for forecast-period business development. Most market players are focusing on developing markets like Asia Pacific owing to increased diabetes incidence and increased awareness of sophisticated therapy in the region. In India, both medical science and major movements have been increasing quickly in recent centuries. Diabetes treatment has become so popular and prevalent in India that individuals from other nations come here to receive therapy for themselves. The most likely and convincing cause for this could be their own country's excessively elevated expenditure on health care triggers.
Diabetes is a chronic disease that is life-threatening without any specific remedy. It is primarily due to the failure of the body to generate or use the hormone insulin efficiently. Diabetes is one of the 21st century's biggest global health hazards. This disease is experienced by more and more individuals every year, which can lead to life-changing problems. According to the International Diabetes Federation (IDF), there were roughly 46 million individuals with diabetes in North America in 2017, which is anticipated to increase to 62 million in 2045. The rise in the incidence of disease during the forecast period is around 35 percent fold.
Regional Market Analysis
During the forecast period, Asia Pacific is anticipated to show the highest development. Due to diet, dna alteration, urbanization and aging, this region has the largest amount of people with diabetes. It is anticipated that increasing diabetes incidences will sustain market growth over the forecast period. Asian nations add more than 60 times to the world's diabetic population, contributing to the development of the region's APDS industry, according to an essay released by NCBI. In addition, industry participants are anticipated to increase the industry by extending their facilities across the region. Johnson & Johnson, for example, introduced its Asia Pacific development hub in 2014 to deliver technological progress and improve treatment quality. Such factors are driving the growth of the market. Due to the existence of advanced healthcare infrastructure, Europe recorded the biggest market share of around 43 percent in 2019, strong customer consciousness and comparatively greater healthcare spending. In addition, public funding to provide greater therapy performance encourages business competitors and scientists to introduce fresh technology. For example, the European Union funded the AP@Home project to improve the quality of life of patients.
Competition in the market
Bigfoot Biomedical also launched its first clinical trial on artificial pancreas in July 2016. The clinical study was performed at three locations, Stanford University School of Medicine in cooperation with Lucile Packard Stanford Children's Hospital and Stanford Children's Health in Palo Alto, CA; William Sansum Diabetes Center in Santa Barbara, CA; and Barbara Davis Center for Diabetes at the University of Colorado School of Medicine in Aurora, CO. Pancreas in the abdominal cavity is about 6 inches lengthy. Pancreas produces the insulin, polypeptide pancreatic, glucagon, and somatostatin essential hormones. Pancreas help with digestion and absorption procedures by secreting the digestive enzyme-containing pancreatic juice. Type 1 diabetes is treated with the Artificial Pancreas Device System. Patients with type 1 diabetes involve numerous amounts of insulin in one day and throughout the year. Also known as the closed-loop system or autonomous system for glycemic control or bionic pancreas is the Artificial Pancreas Device System. The Artificial Pancreas Device System simulates the role of a good pancreatic glucose regulation. The continuous monitoring of glucose is performed by subcutaneously putting the sensor to evaluate the amount of glucose in the fluid around the cells. A transmitter provides to the receiver data on projections of glucose concentration and their frequency of transition. Software for controlling algorithms integrated in an internal controller conducts mathematical calculations to ship dosing instructions to engines, computers or smartphones for insulin infusion. The insulin infusion pump controls the insulin delivery amount to the subcutaneous tissue, depending on the dosing orders.
Medtronic Plc, Bigfoot Biomedical, Johnson & Johnson, Tandem Diabetes Care, Inc., Pancreum, Inc., TypeZero Technologies, LLC, and Beta Bionics are some of the main competitors. Major competitors execute policies for expanding their market share, such as mergers, purchases, partnerships and introducing fresh products. They also focus on studies & growth, as well as a sequence of fresh product clinical studies to stay industry skilled. For example, in October 2016, Medtronic plc announced that its MiniMed Connect portable device is commercially available to the Android operating system for quicker and easier connections to insulin pump and ongoing glucose surveillance information.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.